Paper Details

  1. Home
  2. Paper Details

[Treatment of recurrent herpes labialis using a herpes simplex Type-I subunit vaccine. A prospective randomized double-blind multicenter study].

Author: AltmeyerP, HolzmannH, KimmigW K, KorgerG, PaulE, PetresJ, WassilewS W, WehrenbergO

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of 82 patients with recurrent oral herpes compared a herpes simplex type I subunit vaccine to a placebo. Over an 8-month period, there was no statistically significant difference in the frequency of outbreaks between the vaccine and placebo groups. Both groups showed a reduction in outbreaks, but the placebo group had a slightly greater decrease in recurrence frequency.
Paper Details　
Original Abstract of the Article :
A herpes simplex type I subunit vaccine developed by Behring-Werke (Marburg/Lahn, FRG) was compared with placebo for therapeutic effectiveness in the treatment of recurrent orolabial herpes simplex in a multicentre study involving the major hospitals in Frankfurt/Main (n = 34), Hamburg (n = 18), Gie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1662671

データ提供：米国国立医学図書館（NLM）

Evaluating a Herpes Simplex Subunit Vaccine for Recurrent Cold Sores

This clinical trial investigated the potential of a herpes simplex type I subunit vaccine developed by Behring-Werke to treat recurrent orolabial herpes simplex, a common and often bothersome condition. The study adopted a rigorous prospective, randomized, double-blind, multicenter design, involving a substantial number of participants at major hospitals in Germany. The primary outcome measure was the reduction in the frequency of recurrences. The researchers found no statistically significant difference in the frequency of recurrences between the vaccine and placebo groups, suggesting that the vaccine did not offer a clear advantage over placebo in this context.

The Intricacies of Herpes Treatment: A Tale of Two Groups

The study's findings demonstrate that while both placebo and the vaccine led to a significant decrease in the number of recurrences, the effect of placebo was slightly more pronounced. This intriguing result challenges the traditional view of vaccines as inherently superior to placebos and suggests that the underlying mechanisms of herpes recurrence may be more complex than initially thought.

Navigating the Desert of Herpes Treatments

Finding a reliable and effective treatment for recurrent cold sores can feel like searching for an oasis in the desert. This research provides a valuable insight into the potential of a herpes simplex vaccine, albeit one that requires further investigation to fully understand its role in managing this common condition.

Dr. Camel's Conclusion

While the study's findings suggest that this particular vaccine may not offer a significant advantage over placebo, the research highlights the complexity of herpes recurrence and the need for continued exploration of potential treatments. The journey through the desert of herpes management continues, and this study provides valuable knowledge to guide us on the path to better treatment options.

Date :
  1. Date Completed 1992-02-20
  2. Date Revised 2006-11-15
Further Info :

Pubmed ID

1662671

DOI: Digital Object Identifier

1662671

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.